Amgen Inc (NASDAQ:AMGN)

219.38
Delayed Data
As of 4:00pm ET
 +2.02 / +0.93%
Today’s Change
210.28
Today|||52-Week Range
276.69
-4.58%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$121.4B

Company Description

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Contact Information

Amgen, Inc.
One Amgen Center Drive
Thousand Oaks California 91320-1799
P:(805) 447-1000
Investor Relations:
(805) 447-1060

Employees

Shareholders

Mutual fund holders45.53%
Other institutional32.06%
Individual stakeholders1.00%

Top Executives

Robert A. BradwayChairman, President & Chief Executive Officer
Esteban SantosExecutive Vice President-Operations
Peter H. GriffithChief Financial Officer & Executive Vice President
Mike ZahigianChief Information Officer & Senior Vice President
David M. ReeseExecutive Vice President-Research & Development